Pamrevlumab did not meet its primary endpoint for non-ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-1 trialAnne M. Connolly, Ewa Carrier, Eugenio Mercuri et al.|medRxiv|2025Cited by 3
Pamrevlumab did not meet its primary endpoint for ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-2 trialBrenda Wong, H. Phan, Yann Péréon et al.|medRxiv|2025Cited by 2